Drugs / CSB-111
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05285696 | Sep 2022 → Apr 2023 | — | Cytosite Biopharma Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSB-111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05285696 ↗ |
| Route | Intravenous | “single IV injection of CSB-111” NCT05285696 ↗ |